As ICER's Influence Grows, Group Defends Its Drug Value Assessments

By John Wilkerson / August 10, 2016 at 2:31 PM

The Institute for Clinical and Economic Review is defending its value assessments of drugs as the group grows in importance and as some patient groups complain about its methodology.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.